Page last updated: 2024-12-04

thiophane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1127
CHEMBL ID1379
CHEBI ID48458
MeSH IDM0131418

Synonyms (52)

Synonym
tetrahydro-thiophene
thiacyclopentane
thiophane
THT ,
nsc-5272
thiolane
thiophene, tetrahydro-
nsc5272
thilane
tetramethylene sulfide
tetrahydrothiophen
inchi=1/c4h8s/c1-2-4-5-3-1/h1-4h
CHEBI:48458 ,
thiolan
110-01-0
tetrahydrothiophene ,
tetrahydrothiophene, analytical standard
tetrahydrothiophene, 99%
thiofan [czech]
pennodorant 1073
tetramethylenesulfide
hsdb 6122
einecs 203-728-9
tetrahydrothiofen [czech]
nsc 5272
un2412
pennodorant 1013
ai3-30989
CHEMBL1379
FT-0659266
T0114
thiofan
744eht13fm ,
ec 203-728-9
tetrahydrothiofen
unii-744eht13fm
tetrahydrothiophene [un2412] [flammable liquid]
AKOS006220479
tetrahydrothiophene [mi]
tetramethylene sulphide
un 2412
dtxsid3047760 ,
dtxcid8027743
NCGC00357279-01
tox21_304026
cas-110-01-0
trimethylenesulfide
tetrahydrothiophene-2,2,5,5-d4
W-108699
mfcd00005476
Q412118
EN300-105780
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
saturated organic heteromonocyclic parent
tetrahydrothiophenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
respiration (anaerobic)-- electron acceptors reaction list021

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency27.30600.000221.22318,912.5098AID1259243
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency76.95880.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (19.61)18.7374
1990's1 (1.96)18.2507
2000's14 (27.45)29.6817
2010's23 (45.10)24.3611
2020's3 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.51 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.88 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.85%)6.00%
Case Studies1 (1.92%)4.05%
Observational0 (0.00%)0.25%
Other49 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]